361 Capital’s Regenxbio RGNX Stock Holding History

361 Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$621K	Buy	+16,873	New	+$629K	0.29%	190
2019 Q2	–	Sell	-46,861	Closed	-$2.69M	–	373
2019 Q1	$2.69M	Buy	46,861 +4,257	+10%	+$211K	0.47%	98
2018 Q4	$1.79M	Buy	42,604 +17,582	+70%	+$1.03M	0.37%	153
2018 Q3	$1.89M	Buy	25,022 +107	+0.4%	+$7.71K	0.41%	74
2018 Q2	$1.79M	Buy	+24,915	New	+$1.19M	0.41%	70

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

361 Capital's RGNX Position: Q2 2020 in Review

361 Capital opened a new position in Regenxbio (RGNX) in Q2 2020: 16,873 shares worth $621K. The stake represents 0.29% of the portfolio and ranks #190 among its holdings. This is a return to the name: 361 Capital previously reported a position in RGNX as recently as Q1 2019.

361 Capital first reported a position in RGNX in Q2 2018 and has held it in 5 quarters since. The position peaked at $2.69M in Q1 2019. 179 funds tracked by Wall St. Rank hold RGNX as of Q2 2020.

361 Capital held 16,873 shares of Regenxbio worth $621K as of Q2 2020.
Regenxbio was a new 361 Capital position in Q2 2020.
Regenxbio made up 0.29% of 361 Capital's portfolio in Q2 2020, its #190 holding.
361 Capital first reported a position in Regenxbio in Q2 2018 and has held it in 5 quarters since.
361 Capital's Regenxbio position peaked at $2.69M in Q1 2019.
179 funds tracked by Wall St. Rank held Regenxbio as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.